Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.57 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15372721 | 0.87 | BDKRB1 (0.57) | BDKRB1LMNATSHR | |
| SCHEMBL493089 | 0.87 | ALDH1A1 (0.52) | BDKRB1GSTO1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL4484352 | 0.84 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL4467182 | 0.83 | CNR2 (0.44) | BDKRB1LMNAKEAP1NFE2L2PTGDR2 | |
| SCHEMBL11947869 | 0.83 | ALDH1A1 (0.59) | BDKRB1ACLYALDH1A1L3MBTL1LMNA | |
| SCHEMBL5114284 | 0.82 | HTT (0.48) | BDKRB1GSTO1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL4028398 | 0.81 | ACLY (0.49) | BDKRB1ACLYGSTO1ALDH1A1LMNA | |
| SCHEMBL493487 | 0.80 | KEAP1 (0.52) | ALDH1A1LMNAKEAP1NFE2L2 | |
| SCHEMBL6184726 | 0.80 | ACLY (0.47) | BDKRB1ACLYGSTO1ALDH1A1L3MBTL1 | |
| SCHEMBL14033580 | 0.80 | ALDH1A1 (0.43) | BDKRB1GSTO1ALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885ACLY 2523/4885GSTO1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.